Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension [Phase 3]

View source ↗

Summary

This is the China extension of the Phase 3 KEYNOTE-585 trial evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in gastric and gastroes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Status: COMPLETED | Results posted: 2025-02-20